

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.medine.2022.04.001>.

References

- Morrow CB, McGrath-Morrow SA, Collaco JM. Predictors of length of stay for initial hospitalization in infants with bronchopulmonary dysplasia. *J Perinatol*. 2018;38:1258–65.
- Andersson-Marforio S, Lundkvist Josenby A, Ekvall Hansson E, Hansen C. The effect of physiotherapy including frequent changes of body position and stimulation to physical activity for infants hospitalised with acute airway infections. Study protocol for a randomised controlled trial. *Trials*. 2020;21:803.
- Liberali J, Davidson J, Nunes dos Santos A. Availability of physical therapy assistance in neonatal intensive care units in the city of São Paulo, Brazil. *Rev Bras Ter Intensiva*. 2014;26:57–64.
- Kim ST, Lee J-H. A survey on the current status of neonatal physical therapy in South Korea. *J Korean Phys Ther*. 2020;32:169–76.
- SECIP: Sociedad Española de Cuidados Intensivos Pediátricos [Accessed 3 June 2020]. Available from: www.secip.com/nosotros/cip-en-espana/ucips-en-espana, 2010.
- Lathrop Ponce de León C, Castro Rebollo P. Estado actual de la labor de los fisioterapeutas en las unidades de cuidados intensivos de adultos del área metropolitana de Barcelona. *Fisioterapia*. 2019;41:258–65.
- Valentín A, Ferdinande P, ESICM Working Group on Quality Improvement. Recommendations on basic requirements for intensive care units: structural and organizational aspects. *Intensive Care Med*. 2011;37:1575–87.
- Raurell-Torredà M, Arias-Rivera S, Martí JD, Frade-Mera MJ, Zaragoza-García I, Gallart E, et al. Grado de implementación de las estrategias preventivas del síndrome post-UCI: estudio observacional multicéntrico en España. *Enferm Intensiva*. 2019;30:59–71.
- Unidades de cuidados intensivos: estándares y recomendaciones. Madrid: Ministerio de Sanidad y Política Social; 2010. Available from: www.msc.es/organizacion/sns/planCalidadSNS/docs/UCI.pdf
- Norrenberg M, Vincent J-L, with the collaboration of the European Society of Intensive Care Medicine. A profile of European intensive care unit physiotherapists. *Intensive Care Med*. 2000;26:988–94.

L. Torreiro Diéguez^a, J.-D. Martí^b, S. Souto Camba^{c,d}, L. González Doniz^{c,d}, A. López García^{c,d}, A. Lista-Paz^{c,d,*}

^a *Asociación de Personas con Lesión Medular y Otras Discapacidades Físicas de Galicia (ASPAYM Galicia), A Coruña, Spain*

^b *UCI de cirugía cardiovascular, Instituto Clínico Cardiovascular (ICCV), Hospital Clinic, Barcelona, Spain*

^c *Facultad de Fisioterapia de la Universidade da Coruña. Campus Universitario de Oza, A Coruña, Spain*

^d *Grupo de investigación en Intervención Psicosocial y Rehabilitación Funcional. Universidade da Coruña, Campus Universitario de Oza, A Coruña, Spain*

Corresponding author.

E-mail address: ana.lista@udc.es (A. Lista-Paz).

<https://doi.org/10.1016/j.medine.2022.04.001>
2173-5727/ © 2022 Published by Elsevier España, S.L.U.

Comparison of the clinical characteristics and mortality in acute respiratory distress syndrome due to COVID-19 versus due to Influenza A-H1N1pdm09



Comparación de las características clínicas y mortalidad debidas a Síndrome de Dístres Respiratorio Agudo debido a COVID-19 versus Influenza A-H1N1pdm09

Dear Editor:

Severe pneumonia with the Influenza A-H1N1 virus was first reported in Mexico in April 2009,¹ causing acute hypoxemic respiratory failure (AHRF), acute respiratory distress syndrome (ARDS), with an associated mortality ranging from 25.1–41% at different sites.² The World Health Organization estimates that influenza affect 5–10% of adults and up to 20–30% of children, especially in immunosuppressed, at extremes of life, and in persons with comorbidities³ and causes approximately 390,000 deaths annually.

The outbreak of respiratory infection by the novel SARS-CoV-2 started in December 2019, in Wuhan (Hubei Province),

China.⁴ From this city, the outbreak has been spreading to most countries worldwide in a severe pandemic.⁵ Up to December 3, 2020, the COVID-19 pandemic has given rise to a total of 62 million cases and 1.4 million deaths around the world,⁵ mainly due to respiratory failure, although a long list of complications in various organs and systems have been described. The COVID-19 disease is associated with severe pneumonia, AHRF, and ARDS, requiring intensive care and ventilatory assistance in up to 5% of cases, and with a reported mortality ranging from 30–60% (average 41%) at different sites.⁶ We wondered how case-fatality compares between ARDS-COVID-19 and ARDS-Influenza (A-H1N1), adjusting for known prognostic risk factors and obtained clinical chart information from consecutive patients with Influenza H1N1 (October 2019 to February 2020, prior to the COVID-10 outbreak) and patients with COVID-19 (March 2020 to October 2020). All patients had a positive viral RT-PCR test and fulfilled the 2012 Berlin Definition of Acute Respiratory Distress Syndrome. Patients with Influenza received Oseltamivir at 150 mg daily for at least 5 days, and those with COVID-19 received various treatments that frequently included corticosteroids. The study was approved by the institutional ethics committee and informed consent was not required. The identity of the patients was protected.

Table 1 Demographic and clinical biomarkers and radiologic characteristics of the patients.

Patient characteristics	COVID-19 (n = 147)	Influenza A-H1N1 (n = 94)	p Value
Age (years)	45 ± 11	47 ± 11	0.147
Sex (M/F)	108/39	69/25	0.9
BMI (kg/m ²)	32.3 ± 6.3	34.4 ± 7.5	0.021
Onset of symptoms at hospital admission (days)	9.1 ± 6.4	9.7 ± 3.4	0.462
Time in ICU (days)	15.3 ± 12	15.9 ± 10	0.687
Mortality	58(39.4%)	21(22.3%)	0.005
Fever	129(87.7%)	92(98%)	0.005
Shortness of breath	125(85%)	94(100%)	<0.001
Muscle pain	81(55.1%)	79(84%)	<0.001
Headache	72(48.9%)	63(67%)	0.005
Laboratory measures	Mean (±SD)		
White blood cell count/μl	10.9 ± 4.6	9.1 ± 4.7	0.004
Lymphocyte count/μl	978 ± 738	897 ± 475	0.35
Platelet count × 10 ³ /μl	269 ± 105	200 ± 85	0.001
Creatinine (0.7–1.2 mg/dl)	1.28 ± 1.17	1.37 ± 1.36	0.61
Lactic dehydrogenase (98–192 UI)	468 ± 184	712 ± 366	0.001
Glucose (mg/dl)	140 ± 46	184 ± 97	0.001
Mean arterial pressure (mmHg)	80 ± 10	70 ± 8	<0.001
Heart rate (beats/minute)	82 ± 15	98 ± 14	<0.001
Use of Norepinephrine	55(37.4%)	56(59.5%)	<0.001
PaO ₂ /FiO ₂ (mmHg)	143 ± 58	96 ± 43	<0.001
Tidal volume (ml)	406 ± 54	395 ± 62	0.14
Respiratory rate (breaths/minute)	23 ± 5.1	22 ± 4.6	0.078
PEEP (cm H ₂ O)	11 ± 2	12 ± 3	0.001
Plateau pressure (cm H ₂ O)	28 ± 6	26 ± 4	0.01
Compliance (ml/cm H ₂ O)	26 ± 12	30 ± 9	0.002
SOFA score	5.2 ± 2.3	6.4 ± 2.0	<0.001
Ventilatory ratio	2.4 ± 0.7	2.3 ± 0.5	0.25

Comorbidities were similar in both groups, except for chronic renal failure. All patients had lung opacities in a CT scanning of the thorax. VR, ventilatory ratio. SOFA is the sequential organ failure assessment score (see text).

Clinical and laboratory data were obtained upon admission and during the patients' stay in the unit. High-resolution computed tomography (HRCT) was performed in all patients prior to admission to the respiratory intensive care unit (ICU). We calculated a bedside indicator of wasted ventilation, the ventilatory ratio (VR) as $[1\text{-minute ventilation (mL/min)} \times \text{PaCO}_2 \text{ (mmHg)}] / [\text{predicted body weight} \times 100 \times 37.5]^7$ and the sequential organ failure assessment (SOFA) score, including PaO₂/FIO₂, platelets, bilirubin, creatinine, mean arterial pressure, and use of vasopressors. Glasgow score was the same as all the patients were sedated.

The information obtained was stored in an electronic database and the main outcome was survival from the ICU. Time to death was evaluated by a Cox proportional risk model, comparing the group with COVID-19 and that of the patients with influenza in non-adjusted models, and adjusting for age, gender, obesity, comorbidities, and biomarkers, and mechanical ventilation parameters.

Statistical analysis was performed with SPSS (version 21) and with STATA (version13.0) statistical software packages. Two-sided *p* values of <0.05 were considered statistically significant. **Table 1** presents the main characteristics of patients with influenza (*n* = 94) and with COVID-19 (*n* = 147). Patients with influenza had a slightly higher body mass index (BMI), lactic dehydrogenase glucose, and SOFA score, and a

higher proportion of individuals with obesity, fever, shortness of breath, muscle pain, and headache, with lower neutrophils. Patients with influenza arrived for care in a worse situation (**Table 1**), they were more hypotense, hypoxemic, requiring vasopressors more frequently, with a higher SOFA score. Those with COVID-19 had a higher crude ICU mortality (39% vs. 22%; Fisher exact test; *p* = 0.007; log-rank test, *p* = 0.01), lower respiratory compliance, and spent more days in the prone position. **Table 2** analyzes a multivariate Cox proportional risk model, having as a dependent variable time to death in the ICU and, as an independent variable, the type of virus (COVID-19 vs. influenza) adjusted by age, sex, comorbidities, symptoms, laboratory results, and ventilatory parameters: COVID-19 patients had nearly 4 times more risk for death (OR = 3.7; 95% CI = 1.9–7.4) than patients with influenza (see figure in supplement). Additional variables associated with predicting mortality were the ventilatory ratio, the SOFA score, and BMI, whereas the number of days in prone ventilation was associated with reduced mortality with borderline statistical significance (*p* = 0.055).

Patients with COVID-19 had a substantially higher lethality than those with influenza, despite both being in respiratory failure, both with ARDS, and after considering various predictors of death such as age, sex, some laboratory measurements, and ventilatory parameters, indicating

Table 2 Adjusted multivariate Cox proportional hazard models.

HR	Adjusted 1HR (95% CI)	p	Adjusted 2HR (95% CI)	p
COVID-19	5.1 (2.7–9.7)	<0.001	3.7 (1.9–7.4)	<0.001
SOFA score	1.5 (1.4–1.7)	<0.001	1.3 (1.2–1.5)	<0.001
Glucose (mg/dl)	1.005 (1.002–1.008)	0.002	1.0 (1.0–1.01)	0.02
BMI (kg/m ²)	1.02 (0.99–1.05)	0.13	1.03(1.01–1.06)	0.03
Days in prone position			0.94 (0.88–1.001)	0.055
Ventilatory ratio			2.3 (1.5–3.4)	<0.001

BMI, body mass index; VR, ventilatory ratio; HR, Hazard Ratio. SOFA is the sequential organ failure assessment score (see text). For the crude model (only COVID-19). Log likelihood -371, AIC 744, and BIC 748.

in COVID-19 more severe lung damage and fewer possibilities of recovery. Influenza and COVID-19 may cause severe damage to the lungs, to other organs, and may cause death, and it is unknown whether this may be attributed to direct viral injury, to an exaggerated inflammatory reaction, or to the often mentioned cytokine storm⁸ in addition to personal susceptibility. Patients with COVID-19 have been compared with those with influenza and lacked a difference in cytokine levels.⁸ The findings of CT scanning overlap in the two infections,⁹ but patients with COVID-19 manifested vascular inflammation, and immunothrombosis¹⁰ to a higher degree than those with influenza. In addition, all of our patients received Oseltamivir, and an influenza vaccine of variable affectivity is available, although only a small proportion of our patients were vaccinated (5% of those arriving at the ICU). Most of our patients with COVID-19 received systemic corticosteroids, but an antiviral treatment and a vaccine were not yet available.

Our study shows limitations such as a small cohort of patients coming from a single high specialty center. However, it is prospective, and both cohorts were studied with few weeks of difference.

In conclusion, patients with respiratory failure and ARDS from COVID-19 treated in an ICU entertain a substantially increased risk of death compared with similar patients with Influenza A-H1N1, even adjusting for SOFA score and other relevant risk factors for mortality.

Author contributions

Authors 1 and 4 concept; Authors 2 and 3 data collection; Authors 2 and 4 statistical analysis; Authors 1, 2 and 4 elaboration of the manuscript.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.medin.2021.05.014](https://doi.org/10.1016/j.medin.2021.05.014).

References

1. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quiñones-Falconi F, Bautista E, et al. Pneumonia and respiratory failure from swine-origin influenza a (H1N1) in Mexico. *N Engl J Med*. 2009;361:680–9.

2. Duggal A, Pinto R, Rubenfeld G, Fowler RA. Global variability in reported mortality for critical illness during the 2009–10 influenza a(H1N1) pandemic: a systematic review and meta-regression to guide reporting of outcomes during disease outbreaks. *PLOS ONE*. 2016;11, e0155044.
3. World Health Organization. Influenza (seasonal). Available from: [https://www.who.int/news-room/fact-sheets/detail/influenza-\(seasonal\)](https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)) [01.06.20].
4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395:507–13.
5. World Health Organization. Coronavirus disease (COVID-19) situation report; 2020. Available from: <https://www.who.int/publications/m/item/weeklyepidemiological-update> [cited 05.12.20].
6. Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients with COVID19: a systematic review and meta-analysis of observational studies. *Anaesthesia*. 2020;75:13401349.
7. Sinha P, Calfee CS, Beitler JR, Soni N, Ho K, Matthay MA, et al. Physiologic analysis and clinical performance of the ventilatory ratio in acute respiratory distress syndrome. *Am J Respir Crit Care Med*. 2019;199:333–41.
8. Mudd PA, Crawford JC, Turner JS, Souquette A, Reynolds D, Bender D, et al. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. *Sci Adv*. 2020, <http://dx.doi.org/10.1126/sciadv.abe3024>.
9. Onigbinde SO, Ojo AS, Fleary L, Hage R. Chest computed tomography findings in COVID-19 and influenza: a narrative review. *Biomed Res Int*. 2020;2020, 6928368.
10. Nicolai L, Leunig A, Brambs S, Kaiser R, Joppich M, Hoffknecht M, et al. Vascular neutrophilic inflammation and immunothrombosis distinguish severe COVID-19 from influenza pneumonia. *J Thromb Haemost*. 2020.

C. Hernández-Cárdenas, G. Lugo-Goytia,
D. Hernández-García, R. Pérez-Padilla*

Respiratory Intensive Care Unit, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Mexico

* Corresponding author.

E-mail address: perezpad@gmail.com (R. Pérez-Padilla).

<https://doi.org/10.1016/j.medin.2021.05.014>

0210-5691/ © 2021 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.